TG Therapeutics Inc

21 sept 2026, 19:16 UTC

TG Therapeutics shares are advancing as discussions highlight BRIUMVI's growing momentum and market share gains in the IV anti-CD20 market for relapsing multiple sclerosis.

18 sept 2026, 20:06 UTC

TG Therapeutics is trading modestly higher, rebounding after an earlier pullback, and has now finished higher for three consecutive sessions.

17 sept 2026, 19:54 UTC

TG Therapeutics Inc is moving higher as economic data shows unexpected labor market strength, despite a decline in housing starts.

16 sept 2026, 23:56 UTC

TG Therapeutics Inc is trading lower in after-market hours, retracing from an initial high shortly after the market closed, despite remaining above its 20-day moving average.

15 sept 2026, 23:41 UTC

TG Therapeutics shares are lower in after-market trading amid negative market sentiment. The New York Empire State Manufacturing Index fell sharply, raising investor caution.

14 sept 2026, 19:16 UTC

TG Therapeutics Inc shares are lower today amid broader market declines. CEO Weiss highlighted upcoming catalysts, including a significant treatment administration method.

11 sept 2026, 20:08 UTC

TG Therapeutics shares are declining during Friday's session, despite social media optimism about its subcutaneous BRIUMVI formulation and potential Priority Review Voucher benefits.

10 sept 2026, 20:31 UTC

TG Therapeutics Inc shares are lower in after-market trading, reflecting a decline despite starting the session near the top of their one-month range.

9 sept 2026, 20:07 UTC

TG Therapeutics shares are lower today amid cautious outlook from CEO Weiss and mixed analyst sentiment on sales estimates. Earlier, the stock pulled back from session highs.

4 sept 2026, 20:07 UTC

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

3 sept 2026, 20:07 UTC

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.

2 sept 2026, 20:02 UTC

TG Therapeutics shares are higher as HC Wainwright reiterates its Buy rating. Social media valuations suggest a price range of $78 to $85 per share.

1 sept 2026, 19:54 UTC

TG Therapeutics shares are rising as H.C. Wainwright maintains a Buy rating and sets a price target of $78, indicating significant upside potential.

31 ago 2026, 22:16 UTC

TG Therapeutics Inc. shares showed little change in after-market trading. The stock remains above its 20-day moving average, indicating stability.

28 ago 2026, 19:51 UTC

TG Therapeutics Inc shares are lower today, continuing a decline since Thursday's close. The stock remains above its 20-day moving average.

27 ago 2026, 23:41 UTC

TG Therapeutics Inc shares are lower in after-market hours, reflecting broader market declines. Economic indicators have not alleviated cautious sentiment amid inflation concerns.

26 ago 2026, 19:16 UTC

TG Therapeutics raised its Briumvi revenue guidance to $890-$905 million, contributing to an upgrade of TGTX stock. Shares are trading roughly flat today.

25 ago 2026, 23:36 UTC

TG Therapeutics Inc. shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and near its one-month trading range.

24 ago 2026, 23:21 UTC

TG Therapeutics Inc shares are higher in after-market hours, reflecting positive momentum following Monday's close, despite no specific news driving the movement.

22 ago 2026, 00:02 UTC

TG Therapeutics shares are higher in after-market trading amid positive investor sentiment and discussions of significant price targets of $150 following recent market pressures.

21 ago 2026, 23:01 UTC

TG Therapeutics Inc. is rising in after-market trading, fueled by positive investor sentiment and potential price targets between $150 and $200.

20 ago 2026, 21:01 UTC

TG Therapeutics Inc shares are higher in after-market hours, despite earlier declines. No specific news was identified to explain the price movement.

19 ago 2026, 19:27 UTC

TG Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday. The stock is trading above its 20-day moving average.

17 ago 2026, 19:56 UTC

TG Therapeutics reported Q2 2026 revenue of $240.34 million and raised its full-year outlook to $950 million, driving shares higher during Monday's trading.

14 ago 2026, 21:01 UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

13 ago 2026, 20:02 UTC

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

10 ago 2026, 19:16 UTC

TG Therapeutics Inc shares are lower today amid a broader market decline, with U.S. stock futures dropping following a surprising labor market report.

7 ago 2026, 23:16 UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

6 ago 2026, 20:03 UTC

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

5 ago 2026, 19:56 UTC

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.